Clinical trial
A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.
NCT00838916 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- May 31, 2013
- Enrollment
- 779 (actual)
- Sites
- 337
Conditions
As the registry lists them; a condition with its own page is linked.